Treatment Evaluation

Introduction

Evaluating psychological treatments requires careful consideration of multiple dimensions, including Effectiveness, ethical implications, cultural appropriateness, and the long-term consequences of Treatment choices. This section provides a framework for evaluating treatments and examines the Comparative merits of biological and psychological approaches.

Framework for Evaluating Treatments

1. Effectiveness (Efficacy and Effectiveness)

Efficacy refers to how well a treatment works under ideal, controlled conditions (randomised Controlled trials, or RCTs). Effectiveness refers to how well a treatment works in real-world Clinical settings, where patients may have comorbid conditions, variable adherence, and less Structured treatment delivery.

Evidence hierarchy:

1. Meta-analyses and systematic reviews: Syntheses of multiple RCTs, providing the highest level of evidence by aggregating data across studies and reducing the influence of any single study”s methodological limitations.
2. Randomised controlled trials: Participants are randomly assigned to treatment or control conditions, minimising the influence of confounding variables. RCTs are the gold standard for establishing causality (that the treatment caused the observed improvement).
3. Quasi-experimental designs: Non-random assignment of participants (e.g., waiting-list controls, historical controls). These designs are more susceptible to selection bias but may be necessary when randomisation is impractical or unethical.
4. Case studies and single-case designs: Detailed examination of individual cases. Useful for generating hypotheses and demonstrating that change is possible, but cannot establish causality or generalisability.
5. Expert opinion and clinical consensus: Lowest level of evidence, but can be valuable when higher-level evidence is unavailable.

2. Safety and Side Effects

All treatments carry risks. Drug therapies have physiological side effects; psychological therapies Carry the risk of emotional distress during treatment. The evaluation of any treatment must weigh The potential benefits against the potential harms.

Drug therapy risks:

• Antidepressants: SSRIs can cause nausea, insomnia, sexual dysfunction, weight gain, and emotional blunting. The FDA issued a black box warning for increased risk of suicidal ideation in patients under age 25.
• Antipsychotics: Can cause weight gain, metabolic syndrome, tardive dyskinesia (involuntary movements), and sedation. Second-generation (atypical) antipsychotics have a lower risk of tardive dyskinesia but a higher risk of metabolic side effects.
• Benzodiazepines: Risk of tolerance, dependence, and withdrawal. Long-term use is associated with cognitive impairment.

Psychotherapy risks:

• CBT for anxiety disorders involves exposure to feared stimuli, which can cause significant short-term distress.
• Psychotherapy may temporarily increase symptoms (e.g., discussing traumatic experiences in trauma-focused therapy can initially increase distress).
• Unqualified or unethical therapists can cause harm through inappropriate techniques, boundary violations, or misdiagnosis.

3. Ethical Considerations

Informed consent: Patients must be fully informed about the nature of the treatment, its Potential benefits and risks, and any alternative treatments available. This requires that the Information be presented in a way the patient can understand.

Right to refuse treatment: Competent adults have the right to refuse treatment, even if Treatment would be beneficial. Exceptions may be made when the individual poses a serious risk to Themselves or others.

Non-maleficence: The principle of “first, do no harm” requires that treatments do not cause Unnecessary harm. The potential benefits of treatment must outweigh the risks.

Justice: Treatments must be distributed fairly. This includes equitable access to treatment Regardless of socioeconomic status, ethnicity, or geographical location.

Confidentiality: Patient information must be kept confidential, with limited exceptions (e.g., When there is a risk of harm to the patient or others).

Deception in research: Some psychological research on treatments involves deception (e.g., Placebo conditions in drug trials). Deception must be justified by the scientific value of the Research, and participants must be fully debriefed afterward.

4. Cultural Considerations

Treatments developed and validated in one cultural context may not be equally effective or Appropriate in other cultural contexts. Cultural factors that influence treatment evaluation Include:

• Explanatory models of illness: Different cultures have different beliefs about the causes of mental illness (e.g., spiritual or supernatural causes versus biological or psychological causes). A treatment that is consistent with the patient’s explanatory model is more likely to be accepted and adhered to.
• Stigma: Attitudes toward mental illness and help-seeking vary across cultures. In some cultures, seeking psychological treatment is highly stigmatised, reducing treatment-seeking behaviour.
• Communication styles: Therapeutic approaches that rely on direct verbal expression of emotions (e.g., psychodynamic therapy) may be less effective in cultures that value emotional restraint and indirect communication.
• Family involvement: In collectivistic cultures, involving family members in treatment may be more important and more effective than individual therapy.

Drug Therapy versus Psychotherapy

Elkin et al. (1989): NIMH Treatment of Depression Collaborative Research Program

The National Institute of Mental Health (NIMH) Treatment of Depression Collaborative Research Program was one of the most influential studies comparing the effectiveness of different treatments For depression. The study compared four conditions:

1. Cognitive-behavioural therapy (CBT): 16 sessions of manualised CBT.
2. Interpersonal therapy (IPT): 16 sessions of manualised IPT.
3. Imipramine plus clinical management: A tricyclic antidepressant.
4. Placebo plus clinical management: An inactive pill.

Key findings:

• For less severely depressed patients, all four conditions produced significant improvement, with no significant differences between treatments (including placebo).
• For severely depressed patients, imipramine was significantly more effective than placebo, and CBT was marginally more effective than placebo (though this difference was not statistically significant for the most severe subgroup).
• IPT was significantly more effective than placebo for severely depressed patients.
• There were no significant differences between CBT, IPT, and imipramine.

Evaluation:

• The study was well-designed (randomised, double-blind for the drug conditions, manualised treatments, experienced therapists).
• The finding that placebo was as effective as active treatments for mild depression has important implications, suggesting that mild depression may be responsive to non-specific factors (therapeutic alliance, expectation of improvement).
• The study has been criticised for using highly experienced therapists, which may not generalise to community settings where therapists have less training and experience.
• The sample excluded individuals with comorbid disorders, substance abuse, and suicidal ideation, limiting generalisability to real-world clinical populations.

Hollon et al. (2005): Long-Term Outcomes

Hollon and colleagues conducted a follow-up study comparing CBT, pharmacotherapy (imipramine), and Their combination for depression, with a particular focus on long-term outcomes after treatment Discontinuation.

Key findings:

• Patients who had responded to CBT and were then withdrawn from treatment had significantly lower relapse rates (approximately 30% at 1 year) than patients who had responded to medication and were then withdrawn (approximately 70% at 1 year).
• Patients who received combined treatment (CBT plus medication) and then discontinued both treatments had relapse rates similar to the CBT-only group.
• Patients who continued medication after the acute treatment phase had lower relapse rates than those who discontinued medication.

Interpretation: CBT teaches patients skills and strategies for managing depressive symptoms that Persist after treatment ends. Pharmacotherapy suppresses symptoms while the medication is being Taken, but symptoms return when the medication is discontinued. This finding has important Implications for the long-term management of depression.

Strengths and Limitations of Drug Therapy

Strengths:

• Generally faster onset of therapeutic effects than psychotherapy (though still 2—4 weeks for antidepressants).
• Requires less active effort from the patient than psychotherapy.
• Can be highly effective for severe mental disorders (e.g., antipsychotics for schizophrenia).
• Easier to standardise and monitor than psychotherapy.
• More scalable: medication can be prescribed in primary care settings, while psychotherapy requires specialised training.

Limitations:

• Side effects can be significant and may reduce treatment adherence.
• Does not address the underlying causes of the disorder (psychological, social, environmental).
• Relapse rates after discontinuation are high.
• Risk of dependence (particularly for benzodiazepines and stimulants).
• May be prescribed as a “quick fix” without addressing modifiable psychosocial factors.

Strengths and Limitations of Psychotherapy

Strengths:

• Addresses the underlying cognitive, behavioural, and emotional processes that contribute to the disorder.
• Produces more durable treatment gains (lower relapse rates after treatment ends).
• Teaches skills and strategies that can be applied to future challenges.
• No physiological side effects.
• Can be tailored to the individual’s specific needs and cultural context.

Limitations:

• Slower onset of therapeutic effects than medication.
• Requires significant time, effort, and motivation from the patient.
• More expensive than medication (though cost-effectiveness analyses often favour psychotherapy in the long term due to lower relapse rates).
• Requires access to trained therapists, which may be limited in certain areas.
• More difficult to standardise than medication; therapist effects (differences between therapists in skill, style, and effectiveness) can influence outcomes.
• May not be effective for the most severe cases (e.g., psychotic depression), where medication may be necessary first to stabilise symptoms.

Combination Therapy

For many disorders, the combination of drug therapy and psychotherapy is more effective than either Treatment alone. Combination therapy is particularly recommended for:

• Severe depression: Combination therapy produces higher response rates and faster improvement than either treatment alone.
• Treatment-resistant OCD: Patients who do not respond to ERP alone may benefit from the addition of an SSRI.
• Bipolar disorder: Mood stabilisers (e.g., lithium) are combined with psychoeducation and CBT to improve medication adherence and coping skills.

The Role of Diagnosis

The choice of treatment depends critically on accurate diagnosis. Misdiagnosis can lead to Inappropriate treatment, wasted time and resources, and potentially harmful outcomes. However, the Reliability and validity of psychiatric diagnoses have been questioned:

• Reliability: The degree to which different clinicians agree on a diagnosis. Inter-rater reliability for most DSM-5 disorders is moderate (kappa values of approximately 0.40—0.70), meaning that diagnosis involves a significant degree of subjective judgment.
• Validity: The degree to which a diagnosis represents a real, distinct disorder with a specific aetiology, rather than an arbitrary category imposed on a continuum of symptoms.
• Comorbidity: High rates of comorbidity (the co-occurrence of multiple diagnoses) raise questions about whether the diagnostic categories are truly distinct or whether they reflect overlapping dimensions of psychopathology.

For an overview of abnormal psychology topics, see Abnormal Psychology.

Common Pitfalls

1. Stating that ‘the results show’ without considering whether the findings can be generalised beyond the sample.

2. Confusing the approaches (biological, cognitive, behavioural, psychodynamic, humanistic) and their key assumptions.

3. Describing a study without evaluating its methodology (e.g., sample, controls, ecological validity).

4. Confusing correlation and causation in psychological research evidence.

Summary

The key principles covered in this topic are linked in the sub-pages above. Focus on understanding the definitions, applying the formulas or frameworks, and evaluating strengths and limitations of each approach.

Worked Examples

Worked examples demonstrating the application of key concepts are covered in the detailed sub-pages linked above.